Introduction
Liver complications are frequent and serious causes of morbidity and mortality in patients who undergo haematopoietic SCT (HSCT) following myeloablative conditioning. A variety of etiological factors contribute to liver injury, including: drug toxicity, viral, bacterial and fungal infections, sinusoidal obstruction syndrome (SOS), cholangitis lenta, acute and chronic GVHD (aGVHD, cGVHD) and benign regenerative lesions, in particular nodular regenerative hyperplasia (NRH) or focal nodular hyperplasia (FNH). [1] [2] [3] [4] [5] [6] [7] This latter, the second most common benign solid tumor of the liver, is a rare post-transplant disorder very infrequently reported in the literature. 2 The lesions mimic metastases and secondary malignant tumors. Hepatic nodular lesions have sometimes been reported in adults 3, 6, 7 and children 2,4,5 following chemo and radiation therapy. These asymptomatic solitary nodules more than 1 cm in diameter are termed 'FNH' in the literature. Their pathogenesis is poorly understood but their outcome appears benign.
In a cohort of 138 consecutive post-transplant patients, prospectively followed by liver magnetic resonance imaging (MRI) for the early detection of secondary hemochromatosis, we fortuitously identified 17 patients with FNH. The aims of this study were to ascertain the frequency of FNH in the setting of HSCT, determine their clinical and radiological characteristics and identify the main risk factors for their occurrence.
Materials and methods
A total of 237 patients underwent HSCT at our hospital between October 1999 and April 2006. Overall, 138 were eligible for the study, which required at least one MRI to have been performed either before or after HSCT in the setting of the follow up of secondary hemochromatosis. The study population was 97 children and 41 adults. Median age was 11.7 years (range 0.3-58). Patient characteristics are summarized in Table 1 . MRI was performed in all 138 patients after HSCT up to normalization of their iron excess. Overall, 85 patients had only one MRI, whereas 53 patients had more than one MRI for a total of 240 diagnostic imaging procedures. Taking the last examination for each patient, the median follow-up time post-HSCT was 1754 days (range 0-6042). In 54 patients (39.1%) MRI was performed before HSCT as part of a prospective study. None had revealed nodules. Only one patient with FNH had an MRI before HSCT, which was normal. The diagnosis of the focal hepatic nodules was made by a board-certified radiologist.
MRI examinations were performed on a General Electric system (1.5 tesla), for estimation of hepatic iron concentra-tion, using a validated protocol published first in 1994 by Gandon. 8 Using this method, five gradient echo sequences are performed with the following parameters: T1 weighted gradient echo TR (time of repetition) 120 ms/TE (time of echo) 4 ms/pulse angle 90 1, proton density weighted gradient echo of TR 120 ms/TE 4 ms/pulse angle 20 1, three increasingly T2 weighted gradient echo's of 120/9/20 1 (T2), 120/14/ 20 1 (T2 þ ), and 120/21/20 1 (T2 þ þ ). The MRI field of view was 400 mm, the matrix 256 Â 179 and the slice thickness 10 mm. For each sequence, three regions of interest were drawn in the right lobe of the liver, and two in the left and right paraspinal muscles. These signal intensity values were entered in the algorithm provided by Gandon et al., which is available online (http://www.radio.univ-rennes1.fr/ Sources/EN/HemoCalc15.html). 
Statistical analysis

Results
Overall, 17 cases of FNH were diagnosed between 2.2 and 13.6 years after HSCT (median: 6.4 years). The cumulative incidence 150 months after transplantation was 35% (95% CI: 0.25-0.45). The delay between transplantation and occurrence of FNH must be interpreted with caution because of the retrospective nature of our study. All patients who have developed FNH were children at the time of HSCT, including 11 (64.7%) less than 10 years of age. Ten (58.8%) were female. Twelve (70.6%) received an allogeneic graft; fifteen (88.2%) were treated for a malignant disease (seven AML, seven ALL and one neuroblastoma) and two for a nonmalignant disease (idiopathic aplastic anemia and sickle cell disease). Ten were considered to have a 'high-risk disease'. All but one received a myeloablative preparative regimen (Table 2) : 10 were given a TBI-based regimen (7.5 Gy (single dose) n ¼ 2, 12 Gy (fractionated) n ¼ 8), and six received a BU-based regimen (16 mg/kg n ¼ 5, 20 mg/kg n ¼ 1). Two experienced grade 1 aGVHD and three SOS. The median age at diagnosis of nodules was 13.7 years (range 8.9-22.9). Abbreviations: (a) ¼ high risk included acute leukaemia, myelodysplasia or lymphoid malignancy in second or higher complete remission or refractedblastic phase, second chronic-or accelerated-phase CML; low risk included acute leukaemia, myelodysplasia or lymphoid malignancy in first complete remission and first chronic-phase CML; (b) ¼ sinusoidal obstruction syndrome diagnosed if two clinical (jaundice, unexplained weight gain, ascites and hepatomegaly) or biological features (hyperbilirubinemia) were observed; (c) ¼ acute GVHD; (d) ¼ iron burden is defined by the association of ferritin X1000 ng/ml (normal value: 3-105) and/or liver iron concentration X72 mmol/g of liver (by magnetic resonance imaging) (normal valueo35). 
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All nodular lesions were discovered during imaging studies conducted for the evaluation of secondary hemochromatosis. All 17 patients were asymptomatic. Levels of liver enzyme were normal or subnormal for all but one patient with concomitant hepatic cGVHD. None of the patients had hepatitis B or C or signs of disease relapse. Moreover, none of the children received growth hormone therapy for growth impairment.
Overall, 13 patients had multiple liver lesions (median ¼ 2.8), five being the largest number observed in a single patient. Mean nodule size was 14.8 mm (range 6-40). Lesions were located in both hepatic lobes. On unenhanced MRI, lesions were predominantly slightly hyperintense compared with surrounding parenchyma on fast spin echo T1-W images, isointense on gradient echo T1-W sequences and always hyperintense on T2-W sequences. In dynamic studies with IV bolus injection of gadolinium chelates, all but one patient had lesions strongly enhanced during the arterial phase ( Figure 1 ) and all lesions emitted an isointense signal in the delayed phase (Figure 2) . A central scar was observed in two cases. Dynamic computed tomography scanning was performed in one case: very similar images were observed with strong enhancement in the arterial phase whereas homogeneous density was observed during the delayed phase. Clinical and radiological characteristics of the 17 patients are summarized in Table 2 .
Three lesions were confirmed by histological analysis. One biopsy was performed early due to atypical MRI findings (lack of strong enhancement during the arterial phase). The two other biopsies were performed subsequently because of the appearance of additional hepatic lesions in the liver. The 3 biopsies revealed histological patterns consistent with regenerative nodules (abnormal nodular architecture, vessel and cholangiolar proliferation) with no atypical cells.
By univariate model, only age at time of transplant (o18 versus 418 years) is significantly associated with a higher probability of FNH (P ¼ 0.012). Factors found to be not significant but nonetheless adjusted for multivariate analysis include the status 'high-risk' disease at transplant (P ¼ 0.10), female gender (P ¼ 0.19) and myeloablative regimen (P ¼ 0.19). SOS, hemochromatosis and acute and /or chronic GVHD of the liver were not associated with a higher risk of FNH. In multivariate Cox regression analysis, only age o18 years was significantly associated with the occurrence of FNH (OR 9.2; 95% CI 1.17-72.5). 'High-risk' status of the disease showed a trend towards an increased frequency of FNH (OR 2.72; 95% CI 0.95-7.89). Male gender was close to significance as a protective factor (OR 0.38; 95% CI 0.13-1.14) ( Table 3) .
Six of the 11 female patients who developed FNH had used oral contraception prior to FNH diagnosis and their treatment was not modified. The size of the nodules initially increased in three patients then stabilized; lesions have remained stable for the three other patients'. By 
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Discussion
Benign hepatic regenerating lesions following treatment with chemotherapy, radiation therapy and HSCT have been reported in adults and children. [2] [3] [4] [5] [6] [7] Three histological and clinical entities have been described. First, NRH consists of monoacinar regenerative nodules measuring less than 10 mm in diameter disseminated throughout the liver parenchyma. NRH is often responsible for portal hypertension, ascites, hepatomegaly, unexplained weight gain and/ or unexplained jaundice.
7,9,10 NRH may be clinically misdiagnosed as SOS, acute GVHD of the liver or cholangitis lenta. 7 NRH occured in 22.5% of a series of 103 patients following HSCT, 7 but other investigators have seen much lower prevalence. 11 Second, FNH, corresponds to confluent monoacinar nodules more than 10 mm in diameter associated with a fibrous central scar. The third entity corresponds to large multiacinar regenerative nodules. The two latter entities are asymptomatic. They correspond to the clinical and radiological features found in our 17 patients. The incidence of FNH following chemo and radiotherapy is unclear. In the only published report in the setting of HSCT, the frequency was 0.45% (14 of 3098) in pediatric patients who had been treated for a malignant tumor. 2 All had previously received high-dose chemotherapy followed by autologous HSCT. Ten of these 14 children developed SOS. Our results are strikingly different in that we observed an actuarial probability as high as 35% after a long follow-up of 12.5 years after HSCT and only 3 children experienced SOS. However, the real incidence of FNH is difficult to assess in this study, since most FNH were discovered by chance during routine imaging analyses. It is important to understand the significance of MRI findings following HSCT in order to provide a rapid and reassuring diagnosis without the need for invasive diagnostic procedures. In fact, typical FNH warrants no further investigations. 9, 10 On computed tomography scans FNH is seen as homogeneous, hypoattenuated masses, with rapid contrast enhancement during the arterial phase.
12,13 On MRI, it seems to be iso-or hypointense to the surrounding parenchyma on T1-W sequences and hyperintense on T2-W sequences. A typical intense enhancement (except sometimes for a central scar) is observed after gadolinium injection during the arterial phase with homogenization during the delayed phase. 14 We observed these typical features in our patients. Close clinical and radiological follow-up is recommended, although some cases present with features similar to NRH. 5 Timing and duration of such follow-up remain unclear. Only atypical lesions highly suspicious for diagnoses including carcinoma, adenoma, metastases or other less common malignant masses warrant liver biopsy for histological examination.
Overall, 50% of FNH are diagnosed after the third decade of life, but they have been reported in all age groups. In this study, the median age was 13.7 years. Females were more affected regardless of age. All 17 patients were asymptomatic, with normal liver functions, contrary to published series where up to 22% of patients were reported as symptomatic. [2] [3] [4] [5] [6] [7] [8] [9] [10] The average interval between the HSCT and diagnosis was 6.4 years. Equally short intervals have been reported following high-dose chemotherapy but the delay seems longer with conventional dose chemotherapy. [2] [3] [4] [5] These results suggest that FNH may occur earlier when liver vascular injury is significant (that is, high-dose chemotherapy and BU-containing regimens).
The pathogenesis of FNH remains controversial. Reports suggest that the FNH and NRH could represent different outcomes of a similar circulatory disorder, but the exact underlying pathological mechanism is far from being elucidated. 15 In the general pediatric population, FNH occurs with a prevalence of 0.02%. 2 It supports the fact that the higher prevalence observed in our cohort is probably related to the transplant process. Following SCT, the occurrence of FNH may be linked to the type of conditioning regimen. In our series, six children received a combination of BU (total dose: 16-20 mg/kg) with either cyclophosphamide (total dose: 200 mg/kg) or melphalan (total dose: 180 mg/m 2 ). In all, 10 received TBI combined with one or two alkylating agents, in particular thiotepa and melphalan, known to be associated with vascular lesions in the liver. Moreover, a link with well-characterized endothelial complications including GVHD, SOS, thrombotic microangiopathy could be hypothesized. We failed to find a significant association in our series. The relation between oral contraception and regenerating nodules remains elusive. Data suggest that estrogen induced-FNH reversed by treatment interruption, 16 but these findings have not been confirmed. 17 Other risk factors associated with liver injury following HSCT, such as pre-transplantation abnormal liver enzymes levels and/or HCV (hepatitis C virus)/HBV (hepatitis B virus) positive serologies
18 have yet to be described in FNH. In our cohort, all nodules were diagnosed when the children were surveyed in the setting of severe and prolonged (45 years) hepatic iron overload. To our knowledge, an association between regenerating lesions of the liver and primary or secondary hemochromatosis has never been described even if some reports suggest that the transfusional iron overload might influence the risk of developing SOS. Additionally, we found no statistical association between transfusional iron burden and liver toxicity. The natural history of FNH is characterized by the absence of complications. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In our series, 50% of nodules have grown bigger with a median delay of 47 months, but all remained asymptomatic. No malignant transformation has been reported to date, a reassuring fact considering the incidence of second tumors following HSCT. 19, 20 Overall, our data, the first published in the setting of allogeneic HSCT, indicate that FNH is a process, which occurs commonly after HSCT particularly in children and in patients with 'high-risk disease'. The incidence is increasing with improvement in diagnostic imaging techniques. Hepatic focal hypervascular modular lesions are probably due to post-transplantation endothelial injury, but the physiopathology remains elusive at best. Positive diagnosis relies on typical imaging criteria and negative biological workup. Even if the likelihood of malignant change is quite low, the generally increased risk of second malignancies post transplantation, particularly in young children, warrants continued long-term imaging survey. Systematic biopsy or resection is not necessary. Although a systematic diagnostic workup is not mandatory, awareness of this benign entity is critical.
